Meet Inspiring Speakers and Experts at our 3000+ Global Conference Series Events with over 1000+ Conferences, 1000+ Symposiums
and 1000+ Workshops on Medical, Pharma, Engineering, Science, Technology and Business.

Explore and learn more about Conference Series : World's leading Event Organizer

Back

Man-Wah Tan

Man-Wah Tan

Associate Director and Senior Scientist
Genentech
USA

Biography

Dr. Man Wah Tan started his lab at Genentech in 2010. Prior to this, he was an Associate Professor at Stanford University. He drawn to Genentech because of his newfound passion in translating basic discoveries and understanding of host-pathogen interactions into novel medicine for patients with serious and life-threatening infections. Genentech has a strong record of creating novel medicines from cutting edge science. During his academic career, his laboratory used infection of C. elegans by bacterial pathogens as an experimental system to discover and elucidate molecular mechanisms underlying bacterial pathogenesis and host responses within the context of an intact host. His team identified host and pathogen factors that contribute significantly to the outcome of an infection. They include the involvements of the nervous system, the p38 mitogen-activated protein kinase and insulin signaling pathways of the host, as well as the quorum sensing system of the bacteria, in modulating host-pathogen interactions. They are now interested in validating and extending these findings in mammalian models of infections and in identifying critical nodes.

Research Interest

Dr. Man Wah Tan interested in identifying genetic determinants from bacterial pathogens that are essential for pathogenesis and maintenance of infections in vivo using a combination of genetics, molecular and bioinformatics approaches, with focus on surface-associated molecules. His team also seeks to identify and characterize host factors that are associated with disease progression during infections. Their goals are to define bacterial and/or host factors these could potentially be targeted by small or large molecules for therapeutic interventions to ameliorate diseases, including pneumonia and bacteremia.